The early bi-potential mammalian gonad requires the expression of a Y-linked gene, Sry, during a brief window of time to ensure proper testis development. WT1 and its direct target gene Sf1 function during sex determination as well as in the specified testes and ovaries. We have previously shown that the transcription co-factor CITED2 interacts with WT1 to stimulate the expression of Sf1 in the adrenogonadal primordium to ensure adrenal development. We now show through genetic interactions and expression analyses that Cited2 acts in the gonad with Wt1 and Sf1 to increase the expression of Sry levels to attain a critical threshold to efficiently initiate testis development. Reducing the gene dosage of Wt1 or Sf1 in Cited2 mutant gonads was sufficient to produce partial XY sex reversal while full sex reversal was attained in mutants containing a hypomorphic Sry POS allele. A direct correlation was observed between XY sex reversal and reduced expression levels of Sry and Sf1 during sex determination, which indicated that Sry is a downstream target of the CITED2/WT1/SF1 regulatory pathway. Our results provide in vivo evidence for the identification of the first transcription co-factor to function during mammalian sex determination, as part of the WT1/SF1 regulatory mechanism. This highlights the gene dosage sensitivity of the pathway's effect on Sry levels and embryonic gonad development.
INTRODUCTION
The embryonic gonad primordium, the genital ridge, has the potential to differentiate into two distinct organs: the ovary or testis. Most mammals use a genetic-based mechanism to specify the developmental fate of the genital ridge. The Y chromosome acts as a male dominant determinant due to the presence of Sry, a gene encoding a high-mobility group (HMG)-box DNA binding domain containing transcription factor (1 -3) . The transient expression of SRY in a subpopulation of somatic progenitors cells between E10.5 and E12.5 initiates the differentiation of Sertoli cells and subsequent rapid and dramatic morphological changes in the mouse gonad. Gross testis structures are apparent approximately 48 h after the onset of Sry expression, with Sertoli cell and germ cell aggregates surrounded by peritubular myoid cells forming the testis tubular cords. Between the cords, the interstitial space, reside uncharacterized mesenchymal cells, the steroid producing Leydig cells and male-specific vasculature which are all readily observable within the E13.5 testis (4, 5) .
The identification of Sry, a milestone nearly two decades ago, has been followed with the discovery of a handful of factors functioning during this phase of genital ridge development (6) . These genetic and molecular regulation insights come from multi-species studies involving the analyses of genetic mutations, gene expression and in vitro molecular studies. Several transcription factors implicated in the activation of Sry include the polycomb group protein M33, a specific Wilms' Tumour 1 (WT1) protein isoform, and the GATA4-friend of gata2 (FOG2) complex. Mice with mutant alleles that disrupt these proteins have reduced Sry expression and show XY sex reversal phenotypes (7 -9) . The human disease Frasier syndrome, which is attributable to WT1 mutations, can produce XY sex reversal in heterozygotes (10) . The orphan nuclear receptor, Steroidogenic Factor 1 (Sf1 or Nr5a1), is expressed and functions in the development of the bi-potential gonad. Homozygous null mutant mouse gonads of both sexes degenerate after E11.5 (11) . Sf1 is a direct transcriptional target of WT1 and like human WT1 mutations, heterozygous SF1 mutations can produce XY sex reversal (12 -14) . Consistent with its proposed role in sex determination, in vitro data has shown that SF1 can activate a porcine Sry promoter (15) . A critical regulatory action of SRY is its direct transcriptional activation of the Sox9 gene, an SRY-related HMG-box containing transcription factor (16) . Heterozygous SOX9 humans and homozygous mutant mice containing loss-of-function mutations exhibit XY sex reversal (17 -19) . In contrast, misexpression in these species can generate XX testes indicating Sox9 is necessary and sufficient for testis development (20, 21) . The frequent observation of sex reversal produced by heterozygous mutations in transcription factor encoding genes has led to the suggestion that the sex determination pathway is highly sensitive to gene dosage and/or transcription factor levels (18, 22, 23) .
Genetic background can affect Sry expression which can affect testis development. This is readily apparent in the C57BL/6 (B6) inbred mouse strain and its differential effects on Sry alleles derived from Mus domesticus or Mus musculus mice species (24 allele from the wild-derived M. d. poschiavinus species produce ovaries and ovotestes (25) . Y POS sex reversal is suppressed in other genetic backgrounds including DBA/2 or even (DBA/2 Â B6)F1 hybrids (25) . While Sry MUS levels are reduced in the B6 strain (versus F1 hybrids), the non-coding regulatory region of the Sry POS allele is more sensitive to this background and exhibits even lower transcriptional activity (24) . These data and the heterozygous induced sex reversal phenotypes observed in putative upstream regulators suggest that Sry expression levels are tenuously balanced and that moderate disturbances can substantially influence sex determination and efficient testis differentiation.
The Cited2 gene encodes a non-DNA binding protein that functions as a context dependent transcriptional co-activator or repressor (26, 27) . Genetic studies in mice have revealed its importance in heart, neural tube, left-right patterning and adrenal development (28 -32) . It is expressed in the developing adrenogonadal primordium (AGP) at E10 and continues to be expressed in the adrenal after separation from the AGP. We have previously shown that CITED2 cooperates with WT1 to stimulate the transcription of Sf1 to induce high expression levels, which are required for specification of the adrenal primordium from the AGP (33) . Cited2 expression is also present in the coelomic epithelium and underlying mesenchyme of the E10.5 -E11.5 genital ridge, but in contrast to the adrenal, is subsequently expressed at low levels in gonads of both sexes. No sex reversal is observed in Cited2 2/2 gonads but a transient developmental delay in E11.5 male gonads is detected by reduced Sox9 expression. However, this subtle delay in development is overcome and no developmental defects are observed at later times (33) .
The expression profile of Cited2 during gonad development and its regulation of Sf1 levels during AGP development make it a strong candidate as a factor involved in early gonad development and sex determination. The transient disruption in mutant male gonad development led us to hypothesize that Cited2 mutants reduce the activity of the sex determination pathway to a level that is close to a failure threshold. Here, we provide evidence that Cited2 functions to ensure elevated Sf1 and Sry levels which provide a robust activation of the male pathway as well as proper development.
RESULTS

Genetic interactions between
Cited2 and Wt1 or Sf1 reveal gene dose-dependent roles in sex determination and male gonad development
The reduced Sox9 expression in the Cited2 2/2 ;XY mutant gonad and our previous finding that CITED2 functions with WT1 to stimulate Sf1 gene expression in the AGP suggested that the WT1/SF1 regulatory pathway could be compromised in Cited2 mutant gonads. The evidence for gene dosage effects of WT1 and SF1 in human sex determination led us to test if such effects could be uncovered in the Cited2 mutant background. We generated E13.5 XY gonads with varying gene dosages of Wt1 or Sf1 and Cited2, and analyzed them using double whole-mount in situ hybridization (WISH) with the molecular markers Amh and Fst. The expression of Amh is directly dependent on SOX9 and SF1 and is functionally required to inhibit the development of the female-specific Müllerian duct (34, 35) . Amh is specifically expressed in Sertoli cells of the testis with it first being detected at E12 (36, 37) . The ovarian gene follistatin (Fst) is a downstream target of the WNT4/b-Catenin pathway and is critical to inhibiting the formation of the male-specific vasculature in the XX gonad (38 -40) . Fst is initially expressed at E11.5 and is ovary-specific at E13.5 (38) .
To test the potential sex determination role of Wt1 in the Cited2 mutants, we generated double mutants with different degrees of zygosity for Cited2 and Wt1 null alleles in a mixed MF1ÂB6 genetic background. The only genetic exceptions not produced were Wt1 2/2 containing embryos in which the early loss of the gonad precluded our analyses at E13.5 (41) . Excluding the Cited2 2/2 ;Wt1 þ/2 ;XY gonads, all XY genetic combinations had normal gross morphology. The molecular expression and pattern of Amh confirmed the gross observations ( Fig. 1A -E) . Importantly, no Fst expression was observed in these XY genotypes (n ¼ 21, Table 1 ) while an E13.5 control ovary showed strong expression throughout (Fig. 1I) . In complete contrast to the other XY genotypes, all gonads from Cited2 2/2 ;Wt1 þ/2 ;XY embryos (n ¼ 3, Table 1 ) showed abnormalities ( Fig. 1F-H) . The most extreme example presented an abnormal shape, absence of testicular cords and expressed both Amh and Fst at reduced levels (Fig. 1H) . The Fst and Amh expression were restricted to the anterior and posterior poles of the gonads, respectively, and the Amh expression emphasized the lack of organized cords. The remaining Cited2 2/2 ;Wt1 þ/2 ;XY gonads showed reduced Amh expression in the anterior pole (Fig. 1F,G) . In one gonad, aberrant cord structures and shortened gonad length were compounded to this phenotype (Fig. 1G) . These results show that Cited2 mutant testes can undergo a partial sex reversal when Wt1 dosage is reduced but the most frequent changes are morphological disruptions and reduced male marker expression.
The mild phenotypes produced in the Cited2/Wt1 double mutants encouraged us to look at interactions with the Fig. 2A-E) . Testis cords were of consistent size and distribution in the Cited2 Fig. 2A -C (Fig. 2D) . In marked contrast, all gonads from Cited2 2/2 ;Sf1 þ/2 ;XY embryos (n ¼ 4, Table 1 ) consistently showed expression of the female marker Fst (Fig. 2F -H) . Fst was always observed in the anterior region and while some gonads showed a large domain of Fst expressing cells, other gonads showed a reduced area with lower expression levels ( Fig. 2F,I ,J). Amh expression was posterior to the Fst expression domain, never showed overlap, and was obviously reduced in its level compared with unaffected
Similar to the genetic interactions observed with Wt1, the Cited2 2/2 ; Sf1 þ/2 ;XY gonads showed disorganized testis cords (Fig. 2G) .
Altogether, these studies show that Cited2 genetically interacts with Wt1 and Sf1 to give similar male gonad developmental defects. Both double mutant interactions show that reducing the gene dosage of Wt1 or Sf1 uncovers a functional role for Cited2 during early gonad development and sex determination. Interestingly, the loss of a single functional Sf1 allele is much more severe than loss of a Wt1 allele in Cited2 2/2 gonads.
Sex reversal of Cited2 mutant embryos with a hypomorphic Sry allele
The above results along with the previous observation that Cited2 2/2 testes in a B6 background show a transient developmental delay highlight the sensitized state of the mutant gonad (33) . In the B6 strain, the M. d. poschiavinus (POS) mouse species-derived Y chromosome contains an Sry POS allele that acts as a hypomorph (24) . Sex reversal in B6-XY POS or the hypomorphic activity of an Sry POS transgene can be suppressed by outcrossing to strains such as DBA/2 or C3H/He (24, 25) . Our hypothesis that the sex determination pathway in Cited2 2/2 gonads is 'weak' in all genetic strains suggested the Sry POS allele should fail to initiate the male pathway in a suppressing strain. We tested this by combining the Cited2 mutation with the Y POS chromosome in a mixed genetic background that suppresses the hypomorphic status of the Sry POS allele. Similar to our earlier analyses, we generated E13.5 gonads that contained different gene doses of Cited2 in combination with the Y POS chromosome for WISH. Prior to the generation of Cited2;XY POS 'double mutants', the Y POS chromosome was outcrossed to the C3H/He strain, producing a B6 Â C3H mixed background, to suppress the XY POS sex reversal phenotype. Amh expression was consistently robust and highlighted the testis cords of Cited2 þ/þ ;XY POS gonads (Fig. 3B ). In complete contrast to Cited2 þ/þ ;XX ovaries, we never observed expression of the ovarian marker Fst (n ¼ 10, Table 1 ) in our mixed genetic background (Fig. 3A,B) . Cited2 þ/2 ;XY POS gonads were similar to Cited2 þ/þ ;XY POS in that Amh expression was detected in all gonads (n ¼ 20, Table 1 ). A small number of Cited2 þ/2 ;XY POS gonads (3 of 20) had enlarged or disorganized tubules that were visualized more effectively with the Amh WISH (Fig. 3C) . In striking contrast to the wild-type and heterozygous mutant embryos, morphologically scored ovaries were observed in Cited2 2/2 ; XY POS embryos (2 of 10, Table 1 ) suggesting they had undergone complete XY sex reversal. These gonads showed widespread expression of Fst and a lack of Amh (Fig. 3D) . All of the remaining Cited2 2/2 ;XY POS gonads (8 of 10, Table 1 ) showed an anterior restricted Fst expression while Amh expression, when detected, was always posterior to the Fst expression (Fig. 3E,F We extended this molecular expression analysis using the meiotic specific marker Stra8 and the steroidogenic marker Cyp11a1 in double WISH. Stra8 is a retinoic acid (RA) response gene and is critical for female germ cell development (42, 43) . It is only expressed in female germs cells at E13.5 due to the presence of RA which is metabolized in testes by the male-specific enzyme CYP26B1 (44, 45) . In contrast, Cyp11a1 is male-specific at E13.5 and identifies the testosterone producing Leydig cells. Similar to the Amh/Fst results, Cited2 2/2 ;XY POS gonads showed non-overlapping expression of the male and female markers. The female marker, Stra8, was always anterior to Cyp11a1 expression. Leydig cells, as detected by Cyp11a1, were present but appeared to be reduced in number (Fig. 3G-I) .
These results show that Cited2 homozygous mutants can produce complete XY sex reversal and that the genetic status of the sex determination pathway is critical to revealing this function. Importantly, the ovarian and testicular tissues are spatially exclusive. This suggests that the failure to initiate the male program is an early defect.
Gene dosage-dependent reduction of Sf1 and Sry expression in Cited2/Wt1 and Cited2/Sf1 double mutant gonads
We sought to test if the sex reversal phenotypes observed at E13.5 could be accounted for by molecular changes at the time of sex determination. Using quantitative RT -PCR (qPCR), we analyzed the expression levels of the earliest sexually dimorphic marker and testis determining gene, Sry, as well as the previously identified CITED2 target gene, Sf1, in E11.5 gonads.
We investigated the expression levels in XY Cited2;Wt1 and Cited2;Sf1 double mutant E11.5 gonads. qPCR of Cited2 2/2 ;Wt1 þ/2 gonads, a genotype that produces disorganized testes or partial sex reversal at E13.5, exhibited reduced (Fig. 4B ). Interestingly, a single Sf1 mutation decreased Sry MUS and Sf1 expression 77% in Cited2 heterozygous and homozygous mutants (Fig. 4C) . This contrasts the marginal reduction when a single functional Wt1 allele is deleted (Fig. 4A) . WT1 is an upstream regulator of Sf1 in the AGP and the genital ridge. We found Wt1 levels in Human Fig. S1 ). Taken together, there is a consistent reduction of Sry MUS and Sf1 levels in E11.5
gonads as the number of Cited2 and Sf1 or Wt1 mutant alleles are increased. Furthermore, the E11.5 double mutants with the most severe reductions correlate with genotypes that produced XY sex reversal at E13.5. 2994 (Fig. 4C) . Our previously published data showed that Sf1 expression was reduced in C57BL/6-Cited2 2/2 E10.5 AGP and E11.5 gonads (33) . Robust Sf1 levels still required Cited2 in our mixed genetic background. Indeed, we observed a 61% reduction of Sf1 levels in Cited2 2/2 E11.5 gonads compared with Cited2 þ/þ controls (Fig. 4C ). WISH analyses of Sry expression in E11.5 Cited2/XY POS gonads further confirmed the qPCR data. Cited2 þ/þ ;XY POS gonads (18 tail somites) showed the strongest level of expression throughout the length of the genital ridge (Fig. 5A) . The lowest level of detectable Sry expression was in the age-matched Cited2 2/2 ;XY POS gonads, with heterozygotes showing an intermediate level (Fig. 5B,C) . As expected, no signal was observed in XX gonads (Fig. 5D) . At an earlier stage (15 tail somites), no Sry expression could be detected in Cited2 2/2 ;XY POS gonads while Cited2 þ/þ ;XY POS contained low but detectable Sry expressing cells (data not shown).
These results, similar to the Cited2;Wt1 and Cited2;Sf1 double mutants, show that Sry POS levels are reduced in Cited2 mutants and the lowest expression is in the gonad genotypes that show overt sex reversal 2 days later. Importantly, the reduced Sry and Sf1 expression levels are observed in different strain backgrounds, emphasizing the importance of Cited2 during the temporal phase of sex determination.
Cited2 is expressed in the genital ridge during sex determination
Our finding that Sry expression is reduced in the different mutant gonads suggested Cited2 could be functioning during sex determination. We determined the expression of Cited2 in E11.5 genital ridges using ISH. Similar to E10 AGM expression, Cited2 is expressed in the coelomic epithelium and the underlying mesenchyme (Fig. 5E ). This contrasts with the mesenchyme-restricted expression of Sry at the same developmental time (Fig. 5F) (46) . These data show that Cited2 is expressed within the genital ridge during the time of sex determination and Sry expression.
Cited2 and Sf1 haploinsufficiency act as genetic modifiers in sex determination
Our finding that Cited2 þ/2 ;Sf1 þ/2 ;XY MUS gonads have markedly reduced Sry levels at E11.5 and can have reduced Amh expression and testis cord disorganization at E13.5 suggested the double heterozygotes are tenuously balanced during sex determination (Fig. 2D, 4B ). We tested this by introducing the Y POS chromosome into the Cited2;Sf1 genetic stock and processed E13.5 gonads for WISH using the Fst/Amh marker combination. Similar to previous experiments, Cited2 þ/2 ; Sf1 þ/þ ;XY POS embryos were morphologically normal (0 of 3 embryos), did not express the ovarian marker Fst and strongly expressed Amh (Fig. 6B) . The loss of a single functional Sf1 allele led to a mild ovotestis phenotype (2 of 5 embryos) in Cited2 þ/þ ;Sf1 þ/2 ;XY POS gonads (Fig. 6C ). This was exemplified by the simultaneous expression of Fst and Amh and contrasts our finding that Sf1 þ/2 gonads with an Sry MUS containing Y chromosome develop testes. Double heterozygous embryos (Cited2 þ/2 ;Sf1 þ/2 ;XY POS ) produced gonads with complete XY sex reversal (1 of 5 embryos) or an ovotestis (4 of 5 embryos) phenotype with severely reduced Amh expression and disorganized cords (Fig. 6D and data not shown). These results support the hypothesis that Cited2 þ/2 ;Sf1 þ/2 gonads are extremely sensitive to perturbations in the sex determination pathway and show that certain heterozygous genetic combinations are capable of partial or complete sex reversal.
DISCUSSION
Our understanding of the mechanisms functioning in the sexually non-dimorphic phase of genital ridge development and the upregulation of Sry are limited. Here, we provide evidence for a novel role of the transcriptional co-factor CITED2 during sex determination through a WT1/SF1 regulatory pathway. First, E13.5 Cited2 2/2 gonads can undergo complete XY sex reversal by interacting with a context dependent hypomorphic Sry allele. Second, Cited2 2/2 gonads can exhibit partial XY sex reversal in the context of reduced gene dosage of its known interaction partner WT1 or its immediate downstream target Sf1. Third, the gonad genotypes that show partial or full sex reversal at E13.5 also exhibit the lowest expression levels of Sf1 and Sry during the critical sex determination temporal phase. Even our use of different genetic backgrounds, which can affect the sex determination pathway, does not detectably influence the clear dependence on Cited2. Fourth, the direct reduction of Sf1 levels by reducing the Sf1 gene copy number produces a partial sex reversal and phenocopies the Cited2 mutant gonads. Finally, Cited2 is expressed in the E11.5 genital ridge, during the time when Sry is expressed. As in the E10 AGP, these consistent observations suggest a model in which CITED2 cooperates with WT1 to modulate the Sf1 levels in the genital ridge that in turn activate Sry expression. Cited2 ensures the genital ridge has sufficient Sf1 and Sry levels to robustly engage the male pathway. Importantly, the Cited2-dependent mechanism appears to be through the direct control of levels and does not produce a simple on/off switch output in its absence.
It is clear that SF1 levels have differential responses in the developing gonad. In Sf1 2/2 mice, the complete absence of SF1 prevents gonads of either sex developing due to apoptosis-induced degeneration (41) . This contrasts with gonad development in heterozygous humans or mice. Humans with heterozygous SF1 mutations can exhibit a range of phenotypes from XY sex reversal to gonad dysgenesis while heterozygous mice can show partial sex reversal (this work) or exhibit a developmental delay (13, 14, 47, 48 gonads, suggesting the reduced gonad size is in part due to cell death after sex determination has occurred (Supplementary Material, Fig. S2 ). The reduction in Sf1 levels by deletion of one functional Sf1 allele or disruption of the CITED2/WT1 transcriptional regulatory mechanism prevents the high-level activation of the Sry gene necessary for normal testicular development while providing sufficient SF1 activity to prevent complete gonad degeneration. The integration of these data supports the model that the sex determination mechanism requires a higher SF1 activity to function properly compared with a lower dose necessary to prevent gonad degeneration (49) . It has been suggested that reduced Sf1 levels, as in a Sf1 þ/2 genital ridge, might result in lower Sry expression due to fewer pre-Sertoli cells being specified, proliferating or surviving and not due to a reduction of Sry expression on a per cell basis (6). While we cannot exclude a reduced cell-population effect, previous analyses failed to show any reduced proliferation or increased cell death in Cited2 2/2 AGP and urogenital regions (33) . Also, we found no difference in Lhx9 expression between E11.5 Cited2 2/2 and Cited2 þ/þ gonads (data not shown). Furthermore, while Cited2 2/2 ;Sf1 þ/2 ;XY MUS gonads are smaller at E13.5, E11.5 genital ridges have comparable expression levels of Wt1 to non-sex reversing genotypes (Supplementary Material, Fig. S1 ). These data indicate that Wt1 and Lhx9 expression do not require Cited2 and its absence does not prevent the development of the genital ridge and the expression of these critical genes. Together these observations suggest, albeit indirectly, that Cited2 2/2 E11.5 gonads still have sufficient number of pre-Sertoli cells but fail to upregulate Sry mRNA levels. Interestingly, the large decrease in Sry levels does not appear to be sufficient to always lead to sex reversal as exemplified by the Cited2 þ/2 ;Sf1 þ/2 ;XY MUS gonads. The recent characterization of a Sox9 gonad enhancer provides a possible explanation for these discrepancies (16) . Sox9 regulatory enhancer(s) require SF1 to initiate the low level expression in the E10.5 XX and XY genital ridges. Expression of the SRY protein in the XY gonad allows it to bind directly to the testis-specific enhancer of Sox9 (TES) and synergize with SF1. This interaction strongly upregulates the transcription of Sox9 which is necessary for Sertoli cell specification and testis differentiation. We propose that even though the Sry MUS and Sf1 levels are extremely low in some genetic combinations, there is still enough production of both proteins to activate TES and upregulate Sox9. If this is the case, why do Cited2 2/2 ;XY POS gonads sex reverse? Elegant in vivo experiments using chimeric transgenes of Sry POS and Sry MUS alleles revealed that coding sequence variation of the Sry POS allele produces a less active SRY protein compared with the Sry MUS encoded allele (24) . Therefore, Cited2 2/2 ;XY POS gonads not only have reduced Sf1 and Sry levels but also have an SRY protein isoform that less active than the product of the Sry MUS allele. Our data indicates the identification of not only one of the few genes to function prior to sex determination, but a factor that is involved in the regulation of two key gonadal transcription factors, SRY and SF1.
The primitive gonad exhibits regionally asymmetric developmental potential (50) . In B6-XY POS ovotestes, the anterior and posterior poles produce ovarian tissue while the central region produces testicular tissue (25, 51) . This has been explained by the expression pattern of Sry that initiates in the central region and spreads out to the poles (46, 52) . These observations indicate the early gonad contains regions that gain the potential to induce the male pathway at different times. In Cited2 mutant gonads the anterior region was always the first to become disorganized, show reduced male marker expression or activate the female pathway in all of our genetic combinations. While much more infrequent, we did observe two Cited2 2/2 ;XY POS gonads that were ovarian in the anterior, testicular in the center and lacked male or female identity in the posterior pole. These gradations of phenotypes suggest CITED2 activity has differential importance in the gonadal regions which can be briefly summarized as follow: anterior . posterior . central. The propensity of the poles, prior to the central region, to sex reverse in B6-XY POS and Cited2 mutant gonads supports a model that CITED2 influences these regional differences through its action on Sry. However, the lack of an exact B6-XY POS phenocopy in Cited2 mutants suggests CITED2 is affecting other pathways beyond Sry expression. Alternatively, other transcription co-factors such as the CITED2-related proteins could be partially compensating in the posterior region.
The restricted spatial and temporal expression of Sry suggests its transcriptional regulation is tightly regulated. Beyond the original observation that a 14 kb DNA transgene containing the Sry coding sequence and flanking regions is sufficient to induce XX sex reversal, little in vivo data is available to elucidate the important cis-regulatory elements and the associated trans-acting factors (1) . In vitro studies have shown that different combinations of the transcription factors WT1, SF1 or GATA4 can bind the upstream sequences of the mouse, human and pig Sry genes and influence their transcription (15, 53) . WT1 can bind the Sf1 promoter and direct expression in the genital ridge. CITED2 physically interacts with WT1 and stimulates the transcription of Sf1 (33). The E11.5 expression of Cited2 in the mesenchyme underlying the coelomic epithelium, the same region that expresses Sry, suggests CITED2 could be cell autonomously regulating Sry. CITED2 might directly cooperate with WT1 to directly stimulate the Sry promoter. Alternatively, the CITED2/WT1 complex could directly stimulate Sf1 transcription that in turn affects Sry expression. The in vivo identification of bona fide Sry regulatory elements will be required to test these models.
The CITED2/WT1/SF1 regulatory pathway is highly sensitive to gene dosage effects. In humans, proposed partial loss of function CITED2 alleles have been associated with some congenital heart defects (54). Attempts to identify CITED2 coding sequence changes in patients with primary adrenal disorders have failed (55) . However, Cited2 þ/2 defective adrenal development has only been revealed by interactions with Sf1 and Wt1 heterozygous mutations (33) . The interaction with Y POS suggests Cited2 could be a genetic modifier in mice, similar to the previously identified testis-determining autosomal (Tda) genes (56) . This remains to be seen as no linkage between Cited2 and a mapped mouse modifier have been reported to date. Our data raises the possibility that CITED2 loss-of-function alleles could be genetic modifiers in human gonad development. The XY sex reversal in Cited2 þ/2 ; Sf1 þ/2 ;XY POS mouse gonads suggests CITED2 alleles could modify the sex reversal penetrance in human SF1 or WT1 heterozygotes. Such a retrospective analysis of SF1 and WT1 heterozygous patients might provide a possible sub-classification of the variable gonad phenotypes.
This work establishes the importance of Cited2 during early gonad development and assigns it to a limited group of known factors that function during the pre-sex determination stage and affect Sry expression. Our data show that Cited2 phenotypes are remarkably dosage sensitive. The quantitative effect on its target gene, in the AGP and the genital ridge, make it a good candidate genetic modifier worth assessing in certain human XY sex reversal genetic disorders.
MATERIALS AND METHODS
Mouse strains and breeding
The Wt1 mutant mice, kindly provided by Dr Andreas Schedl, contain a previously described null allele that our laboratory bred to the MF1 outbred genetic background (41) . The Sf1 null allele originally described by Luo et al. (11) was generously provided by Dr Robin Lovell-Badge (NIMR, London, UK) and was maintained on C57BL/6 Â CBA/Ca (B6 Â CBA) mixed genetic background. The Y POS chromosome, kindly provided by Dr Paul Burgoyne (NIMR, London, UK) was derived from a C57BL/6-XY POS fertile male and outcrossed to the C3H/He strain (two generations) and originates from the laboratory of Dr Eva Eicher (The Jackson Laboratory, Bar Harbor, ME, USA). The previously generated Cited2 mutant mice contain a null allele that we maintain on a C57BL/6 genetic background with the standard B6 M. musculus Y chromosome (30 females of a mixed B6 Â C3H genetic background. For the production of Cited2/Sf1/XY POS 'triple' mutants embryos, the C3H/He-Cited2 þ/2 ;XY POS (N2) males from the above cross were mated with Sf1 þ/2 females of the B6 Â CBA mixed genetic background. The day a vaginal plug was detected was defined as embryonic day 0.5 (E0.5). More precise staging for E11 -E11.5 entailed the quantification of tail somite (ts) numbers posterior to the hindlimb and limb morphology was used for confirmation of E13.5 stages. PCR-based genotyping was performed on DNA extracted from tail biopsies or yolk sacs. All procedures followed UK Home Office regulations.
Whole-mount in situ hybridization
Tissues were fixed overnight with 4% paraformaldehyde in PBS at 48C. Samples were subsequently washed in PBS þ 0.1% Triton (PBT) followed by a dehydration series through a methanol gradient (25, 50, 75 and 100%) in PBT. WISH experiments were carried out in an in situ processor (Intavis Insitu Pro VS) as previously described (57) . Double in situ hybridization experiments were performed using the same basic protocol with the minor modification of including the digoxigenin-labeled and fluorescein-labeled RNA probes simultaneously during the hybridization step. The signal from the digoxigenin labeled probe was detected first with the BCIP/NBT substrate mix. Subsequently, samples were fixed with 4% paraformaldehyde for 20 min, heated to 658C in PBT for 30 min and washed two times for 15 min each in 100 mM glycine (pH 2.5) to inactivate the alkaline phosphatase activity associated with the digoxigenin labeled probe. Samples were then washed in TBT (50 mM Tris pH 7.5; 150 mM NaCl; 0.1% Triton), blocked 60 min at room temperature in TBT with 10% sheep serum and followed by an overnight incubation with an alkaline phosphatase-conjugated anti-fluorescein antibody in TBT with 1% sheep serum. Following extensive TBT washes (.6 Â 60 min each), the signal due to the fluorescein labeled probe was detected using the INT/BCIP substrate mix (Roche). Sagital sections were obtained after fixing stained samples for 30 min in 4% paraformaldehyde in PBS at room temperature and sinking through a sucrose (in PBS) gradient and finally in OCT. Samples were frozen, sectioned and mounted in 80% glycerol for visualization. Fluorescein labeled Amh and Cyp11a1 antisense RNA probes were generated using previously described cDNA plasmid templates with a fluorescein labeling mix (37, 58) . DIG labeled Fst and Stra8 antisense RNA probes were produced from PCR templates, which included the T7 RNA polymerase recognition sequence, using a DIG RNA labeling mix (Roche). The Cited2 and Sry probes were generated from previously described cDNA plasmids (33, 59) . PCR fragments were amplified using embryonic ovary cDNA as a template and the following primers (F, forward; R, reverse): Fst, 5 0 -GAAACGTGTGAGAACGTGGA-3 0 (F) and 5 0 -G TAATACGACTCACTATAGGGACACAGCTCATCGCAG A-3 0 (R); Stra8, 5 0 -CTCTGCACATGAAGTGACAC-3 0 (F) and 5 0 -GTAATACGACTCACTATAGGGAAGCAG CCTTTCTCAATG-3 0 (R).
Quantitative real-time RT -PCR
For each E11-11.5 embryo, the two gonads and their associated mesonephroi were microdissected away from the juxtaposed tissue and frozen on dry ice. E11-11.5 embryos were precisely staged using tail somite number. We restricted our analyses to stages of previously reported peak Sry expression and its window of activity: ts14-ts18 (60) . For each genotype, three or four microdissected gonad/mesonephroi pairs were processed separately (biological replicates) as follows. Total RNA was extracted from frozen tissue using the RNAeasy micro kit (Qiagen) according to the manufacturer's protocol. Oligo(dT) primed single stranded cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen). Sry, Sf1, Cyp11a1, Lhx9, Wt1 and Hprt1 sequence amplification was quantified by realtime PCR using the Taqman system (Applied Biosystems).
The following premade and pretested primer/probe set combinations were used: Cyp11a1, Mm00490735_m1; Hprt1, Mm00446968_m1; Lhx9, Mm00495310_m1; Sf1, Mm00446826_m1; Sry, Mm00441712_s1 and Wt1, Mm00460570_m1. The relative mRNA accumulation was determined using the DDCt method with Hprt1 to normalize (61) .
Results are expressed as a percentage of the Cited2 þ/þ or Cited2 þ/2 mean value, depending on the genetic cross. The values are the mean of the genotype sample along with associated standard deviation whiskers.
